Natividad Stover, MD
Neurology · Birmingham, ALNPI 1154341667
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (33.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. MDD US Operations, LLC accounts for 72.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $7,273 and has fallen 72.5% since, to $2,000 in 2025.
Across 37 payments — averaging $343.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$9K
- Jazz Pharmaceuticals Inc.$3K
- Acadia Pharmaceuticals Inc$26
- Merz Pharmaceuticals, LLC$25
Across 24 payments — averaging $23,844 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$487K
- AbbVie$39K
- UCB SA$39K
- Neurocrine Biosciences, Inc.$6K
- MDD US Operations, LLC$756
- Jazz Pharmaceuticals Inc.$700
What the payments were for
- Consulting fees$4,20033%
- Speaking & faculty fees$3,30026%
- Travel & lodging$3,80030%
- Food & beverage$1,41011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 18 | $9,247 |
| Jazz Pharmaceuticals Inc. | 17 | $3,412 |
| Acadia Pharmaceuticals Inc | 1 | $26 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,710 in reported general payments places this provider in the 70th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 49 | $244,072 |
| IngrezzaValbenazine Tosylate | 19 | $210,680 |
| AustedoDeutetrabenazine | 25 | $121,911 |
| NeuproRotigotine | 59 | $58,183 |
| RytaryCarbidopa/Levodopa | 36 | $43,528 |
| GocovriAmantadine Hcl | 12 | $36,383 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 526 | $30,458 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 23 | $12,805 |
| Rasagiline Mesylate | 34 | $12,327 |
| Pramipexole ErPramipexole Di-Hcl | 16 | $9,004 |
| AmantadineAmantadine Hcl | 99 | $8,553 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 140 | $6,209 |
| Carbidopa | 18 | $4,456 |
| Ropinirole ErRopinirole Hcl | 25 | $4,332 |
| Propranolol Hcl ErPropranolol Hcl | 51 | $3,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $26 | $244,07249 claims |
| MDD US Operations, LLCGocovri | $9,247 | $36,38312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.